Preclinical News and Research

RSS
Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Report on shaping marketplace to support successful oncology product launches

Report on shaping marketplace to support successful oncology product launches

Cerenis, Novasep awarded French Government funding for development of CER-001 HDL mimetic

Cerenis, Novasep awarded French Government funding for development of CER-001 HDL mimetic

NovImmune, Genentech sign exclusive licensing agreement for anti-IL-17 antibody

NovImmune, Genentech sign exclusive licensing agreement for anti-IL-17 antibody

Teva comments on FDA's approval of generic Lovenox injection

Teva comments on FDA's approval of generic Lovenox injection

Scientists develop nanoprobe to detect blood vessel growth in tumors

Scientists develop nanoprobe to detect blood vessel growth in tumors

Cell Therapeutics agrees to sell 4,060 shares of Series 6 preferred stock

Cell Therapeutics agrees to sell 4,060 shares of Series 6 preferred stock

Preclinical data of new acamprosate prodrug to be presented at International Fragile X Conference

Preclinical data of new acamprosate prodrug to be presented at International Fragile X Conference

MiMedx Group reports revenues of $322,000 for second-quarter 2010

MiMedx Group reports revenues of $322,000 for second-quarter 2010

Early bird registration for 2nd International Symposium on MR-guided Focused Ultrasound ends on July 31, 2010

Early bird registration for 2nd International Symposium on MR-guided Focused Ultrasound ends on July 31, 2010

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Gladstone Institutes, H. Lundbeck collaborate to identify therapeutic candidates for neurological diseases

Gladstone Institutes, H. Lundbeck collaborate to identify therapeutic candidates for neurological diseases

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.